SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at the Jefferies 2nd Annual Healthcare Conference to be held in New York on June 24-26, 2008.
Jonathan Lim, MD, Halozyme’s President and Chief Executive Officer, will present on Wednesday, June 25, 2008 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) and will discuss the Company’s strategic initiatives, product pipeline and market opportunities.
Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company’s Web site at http://www.halozyme.com. An archived presentation will be available on the Web site for 30 days.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company’s portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
CONTACT: Robert H. Uhl, Senior Director, Investor Relations of Halozyme
Therapeutics, Inc., +1-858-704-8264, ruhl@halozyme.com
Web site: http://www.halozyme.com/
